Administration of ARS-1 or Albuterol in Subjects With Persistent Asthma

Completed · Phase 2 · Has a placebo group

Conditions studied: Asthma

In brief

ARS-1 is being developed for patients as a needleless alternative route of epinephrine administration for the management of refractory asthma symptoms.

Key facts

Study ID
NCT05363670
Run by
ARS Pharmaceuticals, Inc.
People needed
18
Starts
2022-07-28
Expected to finish
2024-02-02
Last updated by the study team
2026-07-14

Who can join

Age: 12 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.